Today: 9 June 2026
Browse Category

NASDAQ:UNH 26 September 2025 - 6 February 2026

UnitedHealth stock slips after hours — here’s what could move UNH next

UnitedHealth stock slips after hours — here’s what could move UNH next

UnitedHealth shares fell 2.7% to $268.55 Thursday, with little change after hours, as investors reacted to Medicare Advantage reimbursement proposals. The Centers for Medicare & Medicaid Services set a Feb. 25 comment deadline and will announce final 2027 rates by April 6. UnitedHealth projected 2026 revenue above $439 billion, down from 2025 estimates. CEO Tim Noel called the proposed rate “disappointing.”
6 February 2026
·
Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom

Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom

The Dow Jones rose 0.6% to 49,403 Monday afternoon, led by Apple and Cisco, while UnitedHealth and 3M lagged. Gold and silver hit new records as the dollar weakened. The Federal Reserve begins a two-day meeting Tuesday, with rates expected to hold steady. Investors await earnings from major tech firms and the Fed’s decision Wednesday.
26 January 2026
·········
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Plus Therapeutics’ CNSide Diagnostics signed a national agreement with UnitedHealthcare to cover its CNSide tumor cell test, effective Sept. 15, potentially reaching over 51 million members. PSTV shares surged about 60% premarket on Sept. 25 after the news. CNSide’s Houston lab secured CLIA accreditation the prior week. Plus Therapeutics also received $1.9 million in non-dilutive funding from CPRIT on Sept. 22.
26 September 2025
···

Stock Market Today

  • NSE Allocates 10% of Annual CSR Fund to Social Stock Exchange
    June 9, 2026, 10:16 AM EDT. The National Stock Exchange (NSE) will deploy 10% of its annual Corporate Social Responsibility (CSR) corpus through the Social Stock Exchange, signaling trust in this market-based platform designed to connect social enterprises with investors. This move aims to enhance transparency and impact investing by leveraging the exchange's resources to support social causes.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop